Treating cancer by targeting a weakness

Article Abstract:

Research on antitumor drugs suggests that it is possible to achieve specificity without toxicity by adopting a new approach to targeting tumor cells. The role of poly-adenosine diphosphate-ribose polymerase 1 (PARP1) inhibitors in killing tumor cells in rats is discussed.

Science & research, HEALTH SERVICES, Cancer Therapy, Ambulatory Health Care Services, Research, Cancer treatment, Adenosine diphosphate

---

Cancer and the Constitution -- choice at life's end

Article Abstract:

A discussion on whether terminally ill adult patients with cancer for whom there are no effective treatments have a constitutional right of access to investigational drugs the attending physicians might consider beneficial is presented.

Legal issues & crime, Company legal issue, Investigations, Terminally ill persons, Terminally ill, Patients' rights

---

A randomized trail of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

Article Abstract:

The study showing that adjuvant chemotherapy with uracil-tegafur has a beneficial effect on the survival of patients with resected stage one adenocarcinoma of the lungs, is presented.

Anticancer Immunostimulant Preps, Usage, Dosage and administration, Lung cancer, Adjuvant chemotherapy

Similar abstracts:

• Abstracts: Preventing cervical cancer by vaccinating against HPV. Laboratory diagnosis and investigation of anaemia. Revised advice on use of imatinib for chronic myeloid leukaemia
• Abstracts: Targeted cancer treatment: Resisting arrest. Cancer drug discovery: the wisdom of imprecision. Cancer fears stall trails for testosterone replacement
• Abstracts: Prescription drug abuse by teens increasing. Kids' mental health coverage 'limited and inadequate.' Lost in transition
• Abstracts: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. Plasma natriuretic peptide levels and the risk of cardiovascular events and deaths
• Abstracts: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. Circulatinng angiogenic factors and the risk of preeclampsia

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.